Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models

Liang,Rui; Zhang,Wei; Song,Ya-Mei

doi:10.3892/mmr.2013.1377

Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models

Authors:
- Rui Liang
- Wei Zhang
- Ya-Mei Song
View Affiliations

Affiliations: Department of Respiratory Medicine, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Respiratory Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: March 15, 2013 https://doi.org/10.3892/mmr.2013.1377
Pages: 1470-1476

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare leptin and interleukin (IL)-6 expression in patients and rat models with chronic obstructive pulmonary disease (COPD). Leptin and IL-6 levels were determined in patients with an acute exacerbation of COPD (AECOPD), stable COPD and in healthy controls. Rat models of COPD were developed, histological and immunohistochemical analyses were performed and leptin and IL-6 levels were determined. Leptin and IL-6 levels in the serum and sputum were higher in patients with AECOPD compared with stable COPD and control patients. In rats, leptin and IL-6 were expressed in bronchial epithelial and inflammatory cells, while leptin expression was observed in alveolar cells and IL-6 expression in blood vessel cells only. Serum levels of leptin and IL-6 were significantly higher in COPD1 and COPD2 rats compared with the control rats, and were even higher in COPD1 rats than COPD2 rats. In conclusion, leptin and IL-6 levels were demonstrated to be associated with the severity of COPD.

View Figures

View References

1	Vogelmeier C, Hederer B, Glaab T, et al: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 364:1093–1103. 2011. View Article : Google Scholar : PubMed/NCBI
2	Calverley PM, Anderson JA, Celli B, et al: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 356:775–789. 2007. View Article : Google Scholar : PubMed/NCBI
3	Struik FM, Duiverman ML, Bladder G and Wijkstra PJ: Effects of non-invasive positive pressure ventilation (NIPPV) in stable chronic obstructive pulmonary disease (COPD). Respir Med COPD update. 4:94–100. 2008. View Article : Google Scholar
4	Murray CJ and Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 349:1498–1504. 1997.PubMed/NCBI
5	Fang X, Wang X and Bai C: COPD in China: the burden and importance of proper management. Chest. 139:920–929. 2011. View Article : Google Scholar : PubMed/NCBI
6	Yoon HI and Sin DD: Confronting the colossal crisis of COPD in China. Chest. 139:735–736. 2011. View Article : Google Scholar : PubMed/NCBI
7	Siafakas NM, Vermeire P, Pride NB, et al: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 8:1398–1420. 1995. View Article : Google Scholar : PubMed/NCBI
8	de Boer WI, Sont JK, van Schadewijk A, Stolk J, van Krieken JH and Hiemstra PS: Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD. J Pathol. 190:619–626. 2000.PubMed/NCBI
9	Lewis MI and Belman MJ: Nutrition and the respiratory muscles. Clin Chest Med. 9:337–348. 1988.
10	Nishimura Y, Tsutsumi M, Nakata H, Tsunenari T, Maeda H and Yokoyama M: Relationship between respiratory muscle strength and lean body mass in men with COPD. Chest. 107:1232–1236. 1995. View Article : Google Scholar : PubMed/NCBI
11	Wouters EF, Groenewegen KH, Dentener MA and Vernooy JH: Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 4:626–634. 2007. View Article : Google Scholar : PubMed/NCBI
12	Broekhuizen R, Vernooy JH, Schols AM, Dentener MA and Wouters EF: Leptin as local inflammatory marker in COPD. Respir Med. 99:70–74. 2005. View Article : Google Scholar : PubMed/NCBI
13	Auwerx J and Staels B: Leptin. Lancet. 351:737–742. 1998. View Article : Google Scholar
14	Yang YM, Sun TY and Liu XM: The role of serum leptin and tumor necrosis factor-alpha in malnutrition of male chronic obstructive pulmonary disease patients. Chin Med J (Engl). 119:628–633. 2006.
15	Lam QL and Lu L: Role of leptin in immunity. Cell Mol Immunol. 4:1–13. 2007.PubMed/NCBI
16	Bellmeyer A, Martino JM, Chandel NS, et al: Leptin resistance protects mice from hyperoxia-induced acute lung injury. Am J Respir Crit Care Med. 175:587–594. 2007. View Article : Google Scholar : PubMed/NCBI
17	Otero M, Lago R, Lago F, et al: Leptin, from fat to inflammation: old questions and new insights. FEBS Lett. 579:295–301. 2005. View Article : Google Scholar : PubMed/NCBI
18	Vernooy JH, Drummen NE, van Suylen RJ, et al: Enhanced pulmonary leptin expression in patients with severe COPD and asymptomatic smokers. Thorax. 64:26–32. 2009. View Article : Google Scholar : PubMed/NCBI
19	Meier U and Gressner AM: Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 50:1511–1525. 2004. View Article : Google Scholar : PubMed/NCBI
20	Sevenoaks MJ and Stockley RA: Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res. 7:702006. View Article : Google Scholar : PubMed/NCBI
21	Schols AM, Creutzberg EC, Buurman WA, et al: Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 160:1220–1226. 1999. View Article : Google Scholar : PubMed/NCBI
22	Bai XL and Xu JY: Smoking to rat blood lean meat, adiponectin, IL-6 and c-reactive protein influence. Chin J Respir Crit Care Med. 9:298–299. 2010.(In Chinese).
23	Sull JW, Kim HJ, Yun JE, et al: Serum adiponectin is associated with smoking status in healthy Korean men. Endocr J. 56:73–78. 2009. View Article : Google Scholar : PubMed/NCBI
24	Trujillo ME, Sullivan S, Harten I, et al: Interleukin-6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab. 89:5577–5582. 2004. View Article : Google Scholar : PubMed/NCBI
25	Fantuzzi G: Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 115:911–919; quiz 920. 2005. View Article : Google Scholar : PubMed/NCBI
26	Rose-John S, Waetzig GH, Scheller J, et al: The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets. 11:613–624. 2007. View Article : Google Scholar : PubMed/NCBI
27	Yanbaeva DG, Dentener MA, Creutzberg EC and Wouters EF: Systemic inflammation in COPD: is genetic susceptibility a key factor? COPD. 3:51–61. 2006. View Article : Google Scholar : PubMed/NCBI
28	Wouters EF: Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2:26–33. 2005. View Article : Google Scholar : PubMed/NCBI
29	Walter RE, Wilk JB, Larson MG, et al: Systemic inflammation and COPD: the Framingham Heart Study. Chest. 133:19–25. 2008. View Article : Google Scholar : PubMed/NCBI
30	Foschino Barbaro MP, Carpagnano GE, Spanevello A, et al: Inflammation, oxidative stress and systemic effects in mild chronic obstructive pulmonary disease. Int J Immunopathol Pharmacol. 20:753–763. 2007.PubMed/NCBI